Skip to main content
eScholarship
Open Access Publications from the University of California

SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway

  • Author(s): Sun, QY
  • Ding, LW
  • Xiao, JF
  • Chien, W
  • Lim, SL
  • Hattori, N
  • Goodglick, L
  • Chia, D
  • Mah, V
  • Alavi, M
  • Kim, SR
  • Doan, NB
  • Said, JW
  • Loh, XY
  • Xu, L
  • Liu, LZ
  • Yang, H
  • Hayano, T
  • Shi, S
  • Xie, D
  • Lin, DC
  • Phillip Koeffler, H
  • et al.

Published Web Location

https://doi.org/10.1002/path.4482
Abstract

© 2014 Pathological Society of Great Britain and Ireland. We investigated the oncogenic role of SETDB1, focusing on non-small cell lung cancer (NSCLC), which has high expression of this protein. A total of 387 lung cancer cases were examined by immunohistochemistry; 72% of NSCLC samples were positive for SETDB1 staining, compared to 46% samples of normal bronchial epithelium (106 cases) (p <0.0001). The percentage of positive cells and the intensity of staining increased significantly with increased grade of disease. Forced expression of SETDB1 in NSCLC cell lines enhanced their clonogenic growth in vitro and markedly increased tumour size in a murine xenograft model, while silencing (shRNA) SETDB1 in NSCLC cells slowed their proliferation. SETDB1 positively stimulated activity of the WNT-β-catenin pathway and diminished P53 expression, resulting in enhanced NSCLC growth in vitro and in vivo. Our finding suggests that therapeutic targeting of SETDB1 may benefit patients whose tumours express high levels of SETDB1.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View